The Scottish Medicines Consortium (SMC), Scotland’s health technology appraisal body, has made its first recommendations for medicines that have been awarded an innovation passport through the UK’s new Innovative Licensing and Access Pathway (ILAP).
The drugs, all to treat cancer, are Gilead Sciences, Inc.’s Trodelvy (sacituzumab govitecan), Amgen, Inc
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?